Verbascoside Protects Mice From Clostridial Gas Gangrene by Inhibiting the Activity of Alpha Toxin and Perfringolysin O

Jian Zhang¹,², Shui Liu¹,², Lining Xia³, Zhongmei Wen¹, Naiyu Hu¹, Tingting Wang¹,², Xuming Deng¹,², Jiakang He¹,⁴* and Jianfeng Wang¹,²*¹

¹ Department of Respiratory Medicine, The First Hospital of Jilin University, Jilin University, Changchun, China, ² Key Laboratory of Zoonosis Research, Ministry of Education, Institute of Zoonosis, College of Veterinary Medicine, Jilin University, Changchun, China, ³ College of Veterinary Medicine, Xinjiang Agricultural University, Ürümqi, China, ⁴ College of Animal Science and Technology, Guangxi University, Nanning, China

OPEN ACCESS

Edited by: Ren-You Gan,
Institute of Urban Agriculture (CAAS), China

Reviewed by: Ciaran Skerry,
University of Maryland, United States
Vuyo Mavumengwana,
South African Medical Research Council, South Africa

*Correspondence: Jiakang He
ahong18@vip.sina.com
Jianfeng Wang
wjf927@jlu.edu.cn

† These authors have contributed equally to this work

Specialty section: This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology

Received: 05 September 2019
Accepted: 10 June 2020
Published: 14 July 2020

INTRODUCTION

Clostridium perfringens (C. perfringens) is a gram-positive anaerobic bacterium that is widely distributed in nature and in the human intestine (Fraser and Collee, 1975). C. perfringens can secrete four major toxins (α, β, ε, and ι) and is accordingly divided into five serotypes, A–E (Titball, 2005). In humans, C. perfringens can cause a variety of diseases, such as food poisoning and gas gangrene, the latter of which can also occur in animals, such as cats, cattle, dogs, sheep, horses, and goats (Verherstraeten et al., 2015). The incubation period of gas gangrene is short, and the infection can become established within 6–8 h (Uzal et al., 2015). More seriously, more than 50% of those infected will continue to develop systemic toxemia, eventually leading to death; thus, without the timely and effective administration of treatment, gas gangrene can lead to serious economic losses (Low et al., 2018). However, the usual treatments, such as antibiotic treatment and surgical treatment for gas gangrene, all have certain disadvantages including but not limited to antibiotic
resistance and amputation injury to patients (Park et al., 2010; Osman and Elhariri, 2013). Thus, it is necessary to find new methods or ideas for the treatment of gas gangrene.

Clostridial gas gangrene is the fulminant infectious disease caused mainly by the interaction of α C. perfringens toxin (CPA) and perfringolysin O (PFO) (Hifumi et al., 2018). CPA, belonging to the family of bacterial zinc-metallo phospholipase enzymes, is produced by all C. perfringens, is encoded by chromosomes, is a major toxin in C. perfringens, and exhibits both phospholipase C and sphingomyelinase activities (van Bunderen et al., 2010; Masataka et al., 2015). In the 1990s, Awad et al. (1995) used CPA mutants to test a gas gangrene mouse model and found that strains lacking the CPA gene showed decreased pathogenicity and less tissue damage after infection. This work confirmed that CPA is the major toxin in gas gangrene. In 2000, Alberto conducted in-depth studies in vivo and showed that the CPA gene is encoded by C. perfringens (Bryant and Stevens, 1996). Thus, this study targets CPA and PFO and aims to reveal a new method for treating gas gangrene.

In this study, two toxin inhibitors were screened from 17 natural compounds by hemolysis to find a potential inhibitor of gas gangrene. The hemolytic data for various compounds are shown in Table 1. Among the 17 kinds of natural compounds, verbascoside has the best inhibitory effect on both toxins, and we thus selected verbascoside as the target compound for this study. Verbascoside is widely distributed in various Chinese herbal medicines and was isolated and extracted from Verbascum sinuaturn by an Italian scientist in 1963 (Speranza et al., 2010; Zhu et al., 2016). Studies have shown that verbascoside has many biological and pharmacological effects, such as anti-inflammatory, antioxidant, antibacterial, antitumor, antifungal, and chelation properties, and can be used in skin cosmetics and herbal medicines and was isolated and extracted from Verbascum sinuaturn by an Italian scientist in 1963 (Speranza et al., 2010; Zhu et al., 2016). Studies have shown that verbascoside has many biological and pharmacological effects, such as anti-inflammatory, antioxidant, antibacterial, antitumor, antifungal, and chelation properties, and can be used in skin cosmetics and herbal medicines. In this study, verbascoside can be fully absorbed within 1 h and reach a high blood concentration and that its bioavailability on delivery via various injection methods does not exceed 25% (Dai et al., 2017; Feng et al., 2018). Based on the aforementioned pharmacological activities, this study found and studied the inhibitory effects of verbascoside on gas gangrene through a series of in vitro and in vivo experiments.

### MATERIALS AND METHODS

#### Bacterial Growth and Reagents

ATCC13124 served as the C. perfringens strain used in this study. Brain heart infusion (BHI) and tryptone soy broth (TSB) were purchased from Qingdao Hope Biol-Technology Co., Ltd. (Qingdao, China). All the tests for C. perfringens in this study were conducted in the P2 laboratory.

Escherichia coli BL21(DE3) containing the PET-28a-PFO plasmid was stored in our laboratory. The protein phospholipase C (CPA) was purchased from Sigma Aldrich, Shanghai, China.

Verbascoside (purity >98%) was purchased from Chengdu Desite Biotech Co., Ltd. (Chengdu, Sichuan, China). Isopropyl β-D-1-thiogalactopyranoside (IPTG) was purchased from Dalian Meilun Biotechnology Co., Ltd. (Dalian, China).

#### Preparation and Purification of PFO

The gene encoding PFO was amplified using primers containing BamHI and XhoI digestion sites, ligated into the PET-28a plasmid, and transformed into DH5α competent cells. After sequencing, the plasmid was extracted, transformed into BL21(DE3) competent cells, and stored at −20°C for the following assays. BL21 (DE3) cells carrying the PET-28a-PFO plasmid were cultured (37°C, 200 rpm) in TSB containing kanamycin until reaching an OD 600 nm of 0.6–0.8. IPTG was added to the cells at a final concentration of 0.5 mM, and the cells were cultured at 16°C for 12 h at 200 rpm. The cells were then centrifuged and resuspended in phosphate-buffered...
saline (PBS) buffer (pH = 7.4). Following sonication (20 Hz, 100 W) and centrifugation (10,000 rpm, 1 h), the supernatant was collected and passed through a His-affinity column (GE Amersham, Shanghai, China). The PFO samples were eluted with 50 mM imidazole, concentrated in PBS buffer (pH = 7.4), and stored at −20°C for the following study. The purchased CPA powder (Sigma Aldrich) was dissolved in PBS buffer and stored at −20°C for further study. The primers used in this study were as follows: F: 5-GCGCGGATCCATGGCTTTATGTCGTTT-3 and R: 5-GCGGCTCGAGGTTAATTGTAATCTAG-3.

**Hemolytic Activity Assay**

First, 2 µL of PFO (8 µg) or CPA (3.2 µg) protein was added to 485.5 µL of PBS buffer supplemented with various concentrations of verbascoside (0, 2, 4, 8, 16, 32 µg/mL) and preincubated at 37°C for 20 min. Then, 12.5 µL of rabbit or sheep red blood cells (2.5%) was added to each group to a final volume of 500 µL, and the mixture was incubated at 37°C for 20 min. After centrifugation (12,000 g, 1 min, 4°C), the supernatant of each sample was collected, and the absorbance was measured at OD543 nm. The sample without protein and verbascoside was used as a negative control, and the sample treated with H2O was used as a positive control.

**Minimal Inhibitory Concentration Determination Assay**

The minimal inhibitory concentration (MIC) value of verbascoside against *C. perfringens* ATCC13124 was determined by the agar dilution method according to a previous study (Beshiru et al., 2019). Briefly, *C. perfringens* ATCC13124 was adjusted to 1 × 10⁵ colony-forming units (CFUs), added to the surface of each blood plate, placed in an anaerobic bag, and incubated at 37°C for 48 h.

**Bacterial Growth Curve Assay**

*Clostridium perfringens* ATCC13124 was inoculated into 50 mL of BHI culture and incubated at 37°C in a 2.5-L anaerobic culture bag until reaching an OD₆₀₀ nm value of 0.3. Then, the bacteria were aliquoted and cocultured with different concentrations of verbascoside (0, 4, 8, 16, 32, 64, or 128 µg/mL). Finally, the bacteria were cultured at 37°C in a 2.5-L anaerobic culture bag. Cell growth was determined every hour by measuring each group of bacteria at OD₆₀₀ nm.

**Lactate Dehydrogenase Assay**

Caco-2 cells (ATCC HTB-37TM) were plated into a 96-well plate at 2.5 × 10⁴ cells per well and placed in a 5% CO₂ incubator for 24 h. Then, verbascoside was diluted to different concentrations (0.25–2 µg/mL) with RPMI 1640 culture medium without serum or antibiotics and added to each well. Finally, PFO (3.8 µg) or PLC (2.4 µg) was added to a final volume of 200 µL in each well. The samples were treated with 0.2% Triton X-100 or RPMI 1640 medium as the positive (A⁺) and negative (A⁻) controls, respectively. The other samples were treated with protein and the indicated concentration of verbascoside (A). After 5 h of incubation in 5% CO₂, the plates were centrifuged at 1,000 rpm for 10 min. The absorbance of the supernatant in each well was measured at a wavelength of 492 nm by adding a cytotoxicity test reagent (LDH; Roche, Basel, Switzerland). The cytotoxicity was calculated according to the following formula: (A−A⁻)/(A⁺−A⁻) × 100%.

**Live/Dead Cell Assay**

Cells were plated in a 96-well plate overnight at a density of 2.5 × 10⁴ cells per well. The protein (PFO 3.8 µg or PLC 2.4 µg), premixed with various concentrations of verbascoside, was added to each well and incubated for 5 h at 5% CO₂. Then, the protective effects of verbascoside on the cells were assessed by using the live/dead (green/red) reagents (Roche) to observe under a fluorescence microscope according to the manufacturer’s instructions.

**Oligomerization Assay**

First, 5 µL of purified PFO (15 µg) protein was added to PBS buffer with different concentrations of verbascoside (0, 8, or 32 µg/mL) and incubated at 37°C for 20 min. Then, 100 µL of 428 mM KCl was added, and the solution was mixed and incubated at 37°C for 10 min. Finally, rabbit red blood cells were added to the system to make the final concentration 0.5%, and the oligomerization reaction of PFO was induced. The total volume of the system was 500 µL. Next, 5× loading buffer without β-mercaptoethanol was added, and the solution was heated at 55°C for 10 min. The formation of PFO oligomers and monomers was monitored by Western blot as described previously (Wang et al., 2015) using the rabbit anti-perfringolysin O antibody (primary antibody; Abcam, Cambridge, United Kingdom) and peroxidase-conjugated antibody (secondary antibody; Proteintech, Beijing, China). His-tagged *Coxiella burnetii* effector protein (30 KD) was used as the loading control and detected with a Histagged antibody.

**In vivo Experiments**

Female BALB/c mice (6–8 weeks old) were purchased from Liaoning Changsheng Biotechnology Co., Ltd. (Changchun, China) and the experiments were approved by and conducted in accordance with the guidelines of the Animal Care and Use Committee of Jilin University.

*Clostridium perfringens* ATCC13124 was inoculated into BHI in an anaerobic culture bag at 37°C until reaching an OD₆₀₀ nm value of 1.5, followed by centrifugation at 5,000 rpm for 5 min to collect the bacteria. Then, the bacteria were resuspended in PBS buffer (pH = 7.4) for further study. In addition, each mouse was subcutaneously administered 100 mg/kg verbascoside after the infection and at 8-h intervals until a predefined time point was reached.

A total of 2 × 10⁸ CFUs of *C. perfringens* ATCC 13124 was intramuscularly injected into mouse legs. The infected mice were treated with verbascoside as described earlier or with DMSO on the same schedule. The dead mice were collected at each time point in each group within 72 h to analyze mortality, and 15 mice were used in each group. For other studies (12 mice per group), 2 × 10⁷ CFUs bacteria were infected into mouse leg muscles by the same treatment method with verbascoside or DMSO as described earlier. At 48 h post-infection, the
mice were sacrificed by cervical dislocation and necropsied. For pathologic examination, the leg muscles were placed in 4% paraformaldehyde, stained with hematoxylin and eosin, and observed under a light microscope. To assess the effect of verbascoside on the bacterial burden of the leg muscles, the muscle of the infected part of the leg was removed, weighed, homogenized in PBS, diluted, and inoculated onto BHI solid agar plates for 18 h at 37°C.

Statistical Analysis

All assay data analyses ($n \geq 3$) were performed using SPSS 19.0 software, and $P$-values were calculated using one-way analysis of variance (ANOVA; *$P < 0.05$ and **$P < 0.01$). The survival data were analyzed using the log rank test (*$P < 0.05$ and **$P < 0.01$).

RESULTS

Verbascoside Inhibited the Hemolytic Activity of PFO and CPA

Some flavonoids have been reported to be effective inhibitors against pore-forming toxins (Li et al., 2013; Wang et al., 2017; Zhou et al., 2017). Here, verbascoside (Figure 1A), a phenylpropanoid, was found to inhibit the hemolytic activity of both the PFO and CPA toxins secreted by *C. perfringens*.

[FIGURE 1](#) Verbascoside inhibits CPA and PFO hemolytic activity. (A) Chemical structure of verbascoside. (B, C) Hemolytic assays were performed by the coincubation of PFO and rabbit red blood cells or CPA and sheep red blood cells in PBS buffer. The hemolytic activity of each sample was determined by comparing the OD$_{543}$ nm values of the supernatant sample and control sample treated with H$_2$O (without verbascoside, used as 100%). The data are shown as the mean ± SD values of three independent experiments. $P$-values were calculated using one-way analysis of variance (ANOVA) (**$P < 0.01$).

[FIGURE 2](#) Verbascoside has no influence on the growth of *C. perfringens*. (A) The MIC value of verbascoside against *C. perfringens* ATCC13124 was determined by agar dilution. (B) Growth curves for the *C. perfringens* strain ATCC13124 administered different concentrations of verbascoside were examined by monitoring the OD$_{600}$ nm of each sample every 60 min.
As shown in Figures 1B,C, in the positive control, the RBCs could be completely lysed by H2O with 100% hemolysis activity. The sample treated with CPA or PFO without verbascoside was used as the 0 µg/mL. When the concentrations of verbascoside ranged from 2 to 32 µg/mL, verbascoside treatment significantly inhibited the hemolytic activity of these toxins in a dose-dependent manner, indicating that verbascoside is an effective inhibitor of both PFO and CPA.

**Verbascoside Does Not Affect the Growth of C. perfringens**

We further performed MIC and bacterial growth curve studies to determine the antibacterial activity of verbascoside against C. perfringens, revealing an MIC assay result (Figure 2A) >256 µg/mL. Similarly, the bacterial growth curve results (Figure 2B) indicate that verbascoside does not affect the normal growth of the bacteria. Together, our results indicate that verbascoside treatment has no influence on C. perfringens viability at the concentrations required for the inhibition of PFO and CPA activity.

**Verbascoside Protects Cells From Damage Induced by PFO or CPA**

*Clostridium perfringens* alpha toxin and PFO in C. perfringens are the main toxins that cause gas gangrene; thus, whether verbascoside could protect cells from these two toxins was also examined. First, we carried out a cytotoxicity test with the drug verbascoside, which did not damage the cells (Figure 3A). Then, this compound was added into the coculture system of cells and PFO or CPA. As shown in Figures 3B,C, verbascoside inhibited the cytotoxicity of these two toxins in Caco-2 cells. Compared with samples not treated with verbascoside, the...
Verbascoside Protects Mice From C. perfringens Infection

A mouse leg muscle model of gangrene was established to determine whether the protection observed in vitro could also be observed in vivo. The legs of ATCC13124-infected mice were markedly red and swollen, accompanied by extensive hyperemia and hemorrhagic clots (Figure 5A). In line with the foregoing observation, verbascoside treatment significantly alleviated such damage, with only a small bleeding point and swelling, which were almost normal compared to those in control mice without infection (Figure 5A). A light microscope revealed that the muscle tissue was seriously damaged, and the inflammatory cells were concentrated in the muscle tissue space in the sample infected with ATCC 13124 (Figure 5B). In contrast, the number of inflammatory cells in the drug group was significantly reduced, and the tissue was intact following treatment with verbascoside (Figure 5B). In addition, the number of bacteria colonized in the leg muscles was significantly reduced after treatment with verbascoside (Figure 5C). As shown in Figure 5D, 93.33% of infected mice died by 32 h post-infection. As expected, the survival rate of mice receiving verbascoside increased by 33.33%, as only 60% of the infected mice died (P = 0.015 by a log rank test). Furthermore, verbascoside treatment delayed the death period peak by nearly 8 h (from 32 h for ATCC 13124-infected mice to 40 h for verbascoside-treated mice) and could thus extend the precious time required for clinical rescue (Figure 5D). Taken together, our results indicated that in mice, verbascoside can provide systemically effective protection against gas gangrene caused by C. perfringens.

**DISCUSSION**

As a gram-positive anaerobic bacterium, C. perfringens is widely distributed in nature and can secrete a variety of toxins, which can lead to a variety of diseases in humans and animals, including gas gangrene (Fraser and Collee, 1975; Verherstraeten et al., 2015). Gas gangrene is mainly caused by the combination of α and theta toxins secreted by C. perfringens, which can lead to the death of infected animals, resulting in great economic losses. However, to date, effective methods for treating gas gangrene include hyperbaric oxygen, surgery, and antibiotics. Among them, surgery can cause substantial physical damage to patients and have a very inconvenient impact on postoperative life. Numerous tetracycline resistance genes have been found in C. perfringens isolates from Sweden, Norway, Denmark, and other places. Thus, novel strategies or agents are needed to fight this bacterial infection (Park et al., 2010; Osman and Elhariri, 2013). In this study, the phenylpropanoid verbascoside, which differs from traditional antibacterial treatments (antibiotics), could inhibit the hemolytic activity of both CPA and PFO, two important pore-forming toxins that critically contribute to C. perfringens pathogenicity. At the cellular level, verbascoside could also effectively protect Caco-2 cells from these two toxins at low concentrations (0.25–2 µg/mL). In particular, verbascoside could reduce the activities of the toxins by inhibiting the oligomerization of PFO. These results could provide sufficient basic data for in vivo research.

Cases of deep injury or improper postoperative care can cause gas gangrene, especially after natural disasters, such as an earthquake. Poor working environments lead to the easy
contraction of gas gangrene, and the time between disease onset and death is typically only 48 h (Wang et al., 2010; Chen et al., 2011). Thus, missing the golden treatment period can have very serious consequences. The animal experimental results in this study demonstrated that verbascoside could remarkably reduce the pathogenic damage of \textit{C. perfringens} gas gangrene (leg muscle) and significantly decrease the colonization of \textit{C. perfringens} in the leg muscles. Furthermore, the survival rate of the infected mice increased by 33.33% following verbascoside treatment, and verbascoside also delayed the outbreak of death, which is ideal for reaching the effective gold standard rescue time for the treatment of gas gangrene. Currently, only hyperbaric oxygen therapy, amputation surgery, and antibiotics are available for the treatment of gas gangrene (Slack, 1976; Anjana et al., 2014; Ryohei et al., 2018), but the aforementioned methods damage the affected body region and do not prolong the effective treatment time. Herein, verbascoside treatment was shown to prolong the treatment time for gas gangrene without causing serious bodily damage, which fills the gap in the treatment of this infection. In addition, PFO can combine with CPA to damage host cells, which eventually leads to tissue hypoxia and benefits the growth and reproduction of \textit{C. perfringens} in anaerobic environments. Although verbascoside exhibited no antibacterial activity against \textit{C. perfringens}, it could simultaneously inhibit the activities of these two toxins in this study. Owing to this inhibitory effect, verbascoside treatment interfered with the establishment of infection by \textit{C. perfringens} and subsequently inhibited the bacterial burden in \textit{C. perfringens}-infected mice. These data showed that, unlike antibiotics, verbascoside treatment may not put survival pressure on \textit{C. perfringens}.

Our laboratory previously found that many Chinese herbal extracts can inhibit the hemolytic activity of pore-forming toxins secreted by bacteria, including \textit{Staphylococcus aureus}, \textit{Listeria monocytogenes}, and \textit{Streptococcus pneumoniae} (Liu et al., 2017; Song et al., 2017; Teng et al., 2017). For example, luteolin can affect the infection of \textit{L. monocytogenes} by inhibiting the production of LLO. Additionally, verbascoside was also identified as an effective inhibitor of \textit{S. pneumoniae} PLY by directly neutralizing its activity (Zhao et al., 2016). Interestingly, the PLY and PFO described in this study are two important toxins.
in the CDC family. Owing to the high structural homology of the CDC family, verbascoside may inhibit the activities of other CDCs, such as SLY and LLO. Therefore, verbascoside may be used as a potential candidate against infections of bacteria that produce CDCs. However, after 50 mg/mL verbascoside was intramuscularly injected into rats, the C\textsubscript{max} in mice was approximately 20,000 ng/mL (Feng et al., 2018), which indicated that the bioavailability of this compound was relatively low. Thus, further studies should be performed to improve the bioavailability of verbascoside.

In summary, we offer a new strategy for the treatment of gas gangrene by inhibiting CPA and PFO. This strategy also plays a role in the treatment of other pathogenic infections, indicating that verbascoside is a potential lead compound for the treatment of gas gangrene.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

**REFERENCES**

Alape-Giron, A., Flores-Diaz, M., Guilloudard, I., Naylor, C. E., Titball, R. W., Rucavado, A., et al. (2000). Identification of residues critical for toxicity in *Clostridium perfringens* phospholipase C, the key toxin in gas gangrene. *Eur. J. Biochem.* 267, 5191–5197.

Anjana, C., Awad, M. M., Hiscox, T. J., Cheung, K. J., Choo, J. M., Dena, L., et al. (2014). Opioid analgesics stop the development of clostridial gas gangrene. *J. Infect. Dis.* 210, 483–492. doi: 10.1093/infdis/jiu101

Awad, M. M., Bryant, A. E., Stevens, D. L., and Rood, J. I. (1995). Virulence studies on chromosomal alpha-toxin and theta-toxin mutants constructed by allelic exchange provide genetic evidence for the essential role of alpha-toxin in *Clostridium perfringens*-mediated gas gangrene. *Mol. Microbiol.* 15, 191–202. doi: 10.1111/j.1365-2958.1995.tb02234.x

Beshiru, A., Igbinosa, I. H., and Igbinosa, E. O. (2019). Prevalence of antimicrobial resistance and virulence gene elements of *Salmonella* serovars from ready-to-eat (RTE) shrimps. *Front. Microbiol.* 10:1613. doi: 10.3389/fmicb.2019.01613

Bryant, A. E., and Stevens, D. L. (1996). Phospholipase C and perfringolysin O from *Clostridium perfringens* upregulate endothelial cell-leukocyte adherence molecule 1 and intercellular leukocyte adherence molecule 1 expression and induce interleukin-8 synthesis in cultured human umbilical vein endothelial cells. * Infect. Immun.* 64, 358–362. doi: 10.1128/iai.64.1.358-362.1996

Chen, E., Deng, L., Liu, Z., Zhu, X., Chen, X., and Tang, H. (2011). Management of gas gangrene in Wenchuan earthquake victims. *J. Huazhong Univ. Sci. Technol.* 31:83. doi: 10.1007/s11596-011-0155-3

Dai, X. Y., Su, S. L., Cai, H. D., Wei, D. D., Zheng, T. Y., Zhu, Z. H., et al. (2017). Comparative pharmacokinetics of acetoside from total glycoside extracted from leaves of *Rehmannia* and *Dihuangye* total glycoside capsule in normal and diabetic nephropathic rats. *Biomed. Chromatogr.* 31:e4013. doi: 10.1002/bmc.4013

Etemad, L., Zafari, R., Moallem, S. A., Vahdati-Mashhadian, N., Skouei Shirvan, Z., and Hoseinzadeh, H. (2016). Teratogenic effect of verbascoside, main constituent of *Lippia citriodora* leaves, in mice. *Iran. J. Pharm. Res.* 15, 521–525.

Feng, B., Song, Y., Xu, Q., Xu, P., Zeng, Q., Shan, B., et al. (2018). Simultaneous determination of savaside A, acetoside, and isoacetoside in rat plasma by UHPLC-MS/MS: comparative pharmacokinetic and bioavailability characteristics of *Monochasma savatieri* via different routes of administration. *J. Separ. Sci.* 41, 4408–4418. doi: 10.1002/jssc.201800545

**ETHICS STATEMENT**

The animal study was reviewed and approved by the Animal Care and Use Committee of Jilin University.

**AUTHOR CONTRIBUTIONS**

JW, JH, and JZ conceived and designed the experiments. JZ, SL, LX, ZW, NH, and TW performed the experiments. XD contributed reagents, materials, and analysis tools. JW, JH, and JZ wrote the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (grant nos. 81861138046 and 317772782), the National Key Research and Development Program of China (no. 2018YFD0500300), and the Fundamental Research Funds for the Central Universities.

Fraser, A. G., and Collee, J. G. (1975). The production of neuraminidase by food poisoning strains of *Clostridium welchii* (C. perfringens). *J. Med. Microbiol.* 8, 251–263. doi: 10.1099/00222615-8-2-251

Hifumi, T., Nakano, D., Chiba, J., Takahashi, M., Yamamoto, A., Fujisawa, Y., et al. (2018). Combined therapy with gas gangrene antitoxin and recombinant human soluble thrombomodulin for *Clostridium perfringens* sepsis in a rat model. *Toxicon* 141, 112–117. doi: 10.1016/j.toxicon.2017.12.043

Johnson, B. B., and Heuck, A. P. (2014). Perfringolysin O structure and mechanism of pore formation as a paradigm for cholesterol-dependent cytolysins. *Sub Cell. Biochem.* 80, 63–81. doi: 10.1007/978-94-017-8881-6_5

Kostykiv, V. A., Potapovych, A. I., Suhani, T. O., de Luca, C., and Korkina, L. G. (2011). Antioxidant and signal modulation properties of plant polyphenols in controlling vascular inflammation. *Eur. J. Pharmacol.* 658, 248–256. doi: 10.1016/j.ejphar.2011.02.022

Li, J., Adams, V., Bannam, T. L., Miyamoto, K., Garcia, J. P., Ural, F. A., et al. (2013). Toxin plasmids of *Clostridium perfringens*. *Microbiol. Mol. Biol. Rev.* 77, 208–233.

Liu, B., Teng, Z., Wang, J., Lu, G., Deng, X., and Li, L. (2017). Inhibition of listeriolysin O oligomerization by lutein prevents *Listeria monocytogenes* infection. *Fitoterapia* 116, 45–50. doi: 10.1016/j.fitote.2016.11.012

Low, L. Y., Harrison, P. F., Gould, J., Powell, D. R., Choo, J. M., Forster, S. C., et al. (2018). Concurrent host-pathogen transcriptional responses in a *Clostridium perfringens* murine myonecrosis infection. *mbio* 9:e00473-18. doi: 10.1128/mbio.00473-18

Masatoka, O., Yutaka, T., Jun, S., and Masahiro, N. (2015). Membrane-binding mechanism of clostridium perfringens alpha-toxin. *Toxins* 7, 5268–5275. doi: 10.3390/toxins7124880

Mazzon, E., Esposito, E., Di Paola, R., Riccardi, L., Caminiti, R., Dal Toso, R., et al. (2009). Effects of verbascoside biotechnologically produced by *Syringa vulgaris* plant cell cultures in a rodent model of colitis. *Naunyn Schmiedebergs Arch. Pharmacol.* 380, 79–94. doi: 10.1007/s00210-009-0400-5

Osman, K. M., and Elhariri, M. (2013). Antibiotic resistance of *Clostridium perfringens* isolates from broiler chickens in Egypt. *Rev Sci Tech Oie.* 32, 841–850. doi: 10.20506/rst.32.2212

Park, M., Rooney, A. P., Hecht, D. W., Li, J. H., McClane, B. A., Nayak, R., et al. (2010). Phenotypic and genotypic characterization of tetracycline and minocycline resistance in *Clostridium perfringens*. *Arch. Microbiol.* 192, 803–810. doi: 10.1007/s00210-010-0605-5

Rhee, O., Hiroyuki, K., Jun, K., Naoko, I., Katsunori, M., Takeaki, M., et al. (2018). Successful treatment of hepatic gas gangrene by open drainage: a case
report and review of the Japanese literature. Int. J. Surg. Case Rep. 49, 121–125. doi: 10.1016/j.ijscr.2018.06.028
Slack, W. K. (1976). Hyperbaric oxygen therapy in anaerobic infections: gas gangrene. Proc. R. Soc. Med. 69, 326–327. doi: 10.1177/003591577606900304
Song, M., Teng, Z., Li, M., Niu, X., Wang, J., and Deng, X. (2017). Epigallocatechin gallate inhibits Streptococcus pneumoniae virulence by simultaneously targeting pneumolysin and sortase A. J. Cell. Mol. Med. 21, 2586–2598. doi: 10.1111/jcmm.13179
Speranza, L., Franceschelli, S., Pesce, M., Reale, M., Menghini, L., Vinciguerra, I., et al. (2010). Antiinflammatory effects in THP-1 cells treated with verbascoside. Phytother. Res. 24, 1398–1404. doi: 10.1002/ptr.3173
Teng, Z., Shi, D., Liu, H., Shen, Z., Zha, Y., Li, W., et al. (2017). Lysionotin attenuates Staphylococcus aureus pathogenicity by inhibiting alpha-toxin expression. Appl. Microbiol. Biotechnol. 101, 6697–6703. doi: 10.1007/s00253-017-8417-z
Tithball, R. W. (2005). Gas gangrene: an open and closed case. Microbiology 151, 2821–2828. doi: 10.1099/mic.0.28248-0
Uzal, F. A., McClane, B. A., Cheung, J. K., Theoret, J., Garcia, J. P., Moore, R. I., et al. (2015). Animal models to study the pathogenesis of human and animal Clostridium perfringens infections. Vet. Microbiol. 179, 23–33. doi: 10.1016/j vetermic.2015.02.013
van Bunderen, C. C., Bomers, M. K., Wesdorp, E., Peerbooms, P., and Veenstra, J. (2010). Clostridium perfringens septicaemia with massive intravascular haemolysis: a case report and review of the literature. Netherlands J. Med. 68, 343–346.
Verherstraeten, S., Goossens, E., Valgaeren, B., Peerbooms, P., and Veenstra, J. (2010). Clostridium perfringens septicaemia with massive intravascular haemolysis: a case report and review of the literature. Netherlands J. Med. 68, 343–346.
Vertuani, S., Beghelli, E., Scalambra, E., Malisardi, G., Copetti, S., Dal Toso, R., et al. (2011). Activity and stability studies of verbascoside, a novel antioxidant, in dermo-cosmetic and pharmaceutical topical formulations. Molecules 16, 7068–7080. doi: 10.3390/molecules16087068
Wang, J., Liu, B., Teng, Z., Zhou, X., Wang, X., Zhang, B., et al. (2017). Phloretin attenuates listeria monocytogenes virulence both in vitro and in vivo by simultaneously targeting listeriolysin O and sortase A. Front. Cell. Infect. Microbiol. 7:9. doi: 10.3389/fcimb.2017.00009
Wang, J., Qiu, J., Tan, W., Zhang, Y., Wang, H., Zhou, X., et al. (2015). Fisetin inhibits Listeria monocytogenes virulence by interfering with the oligomerization of listeriolysin O. J. Infect. Dis. 211, 1376–1387. doi: 10.1093/infdis/jiu520
Wang, Y., Hao, P., Lu, B., Yu, H., Huang, W., Hou, H., et al. (2010). Causes of infection after earthquake, China, 2008. Emerg. Infect. Dis. 16, 974–975. doi: 10.3201/eid1606.091523
Zhao, X., Li, H., Wang, J., Guo, Y., Liu, B., Deng, X., et al. (2016). Verbascoside alleviates pneumococcal pneumonia by reducing pneumolysin oligomers. Mol. Pharmacol. 89, 376–387. doi: 10.1124/mol.115.100610
Zhou, X., Zhang, B., Cui, Y., Chen, S., Teng, Z., Lu, G., et al. (2017). Curcumin promotes the clearance of listeria monocytogenes both in vitro and in vivo by reducing Listeriolysin O Oligomers. Front. Immun. 8:574. doi: 10.3389/fimmu.2017.00574
Zhu, M., Zhu, H., Tan, N., Wang, H., Chu, H., and Zhang, C. (2016). Central anti-fatigue activity of verbascoside. Neurosci. Lett. 616, 75–79. doi: 10.1016/j.neulet.2016.01.042

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Zhang, Liu, Xia, Wen, Hu, Wang, Deng, He and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.